Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics

Arcturus Therapeutics Holdings Inc. (ARCT)

Today's Latest Price: $67.30 USD

1.15 (-1.68%)

Updated Jan 20 6:55pm

Add ARCT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARCT Stock Summary

  • With a one year PEG ratio of 0.64, Arcturus Therapeutics Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.04% of US stocks.
  • ARCT's price/sales ratio is 160.52; that's higher than the P/S ratio of 97.24% of US stocks.
  • Revenue growth over the past 12 months for Arcturus Therapeutics Holdings Inc comes in at -46.19%, a number that bests merely 6.23% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arcturus Therapeutics Holdings Inc are EVGN, CLDX, KALV, SYBX, and FULC.
  • ARCT's SEC filings can be seen here. And to visit Arcturus Therapeutics Holdings Inc's official web site, go to

ARCT Stock Price Chart Interactive Chart >

Price chart for ARCT

ARCT Price/Volume Stats

Current price $67.30 52-week high $129.71
Prev. close $68.45 52-week low $8.51
Day low $66.41 Volume 1,873,300
Day high $72.48 Avg. volume 2,859,467
50-day MA $74.57 Dividend yield N/A
200-day MA $51.92 Market Cap 1.65B

Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio

Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.

ARCT Latest News Stream

Event/Time News Detail
Loading, please wait...

ARCT Latest Social Stream

Loading social stream, please wait...

View Full ARCT Social Stream

Latest ARCT News From Around the Web

Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.

Why Arcturus Therapeutics Stock Skyrocketed Today

Shares of Arcturus Therapeutics (NASDAQ: ARCT) were skyrocketing 40.9% higher as of 3:10 p.m. EST on Thursday. The huge gain came after Wells Fargo analyst Jim Birchenough initiated coverage on the stock with an overweight rating. Arcturus' shares plunged in December after the company announced updated results from a phase 2 study of COVID-19 vaccine candidate ARCT-021 that disappointed investors.

Yahoo | January 7, 2021

Did You Miss Out on the Chance for Big Gains from Arcturus Stock?

The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.

Yahoo | January 6, 2021

Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates

The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.

Yahoo | January 6, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics to Present at Upcoming Investor Conference

Yahoo | January 6, 2021

Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study

Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.

Yahoo | January 5, 2021

Read More 'ARCT' Stories Here

ARCT Price Returns

1-mo -43.19%
3-mo 36.32%
6-mo 25.33%
1-year 444.06%
3-year 618.25%
5-year 88.15%
YTD 55.14%
2020 299.08%
2019 139.96%
2018 -43.02%
2017 -45.92%
2016 -66.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8616 seconds.